Tiziana Life Sciences Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) After Six Months of Dosing with Intranasal Foralumab
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced positive developments regarding its intranasal foralumab treatment for non-active secondary progressive multiple sclerosis (SPMS). The second Expanded Access patient (EA2) exhibited improved walking ability, requiring no cane for 100 meters, and showed a clinically significant 0.5 point decrease on the Expanded Disability Status Scale (EDSS). These results will be further evaluated with PET imaging to assess microglial activation in Q4 2022. The company plans to enroll four additional patients at Brigham and Women’s Hospital during the same period.
- EA2 patient demonstrated improved walking ability measured by gait stability.
- Clinically significant improvement in EDSS score by 0.5 points.
- Patient's pyramidal score remained stable without deterioration.
- Plans to enroll four additional SPMS patients in Q4 2022.
- None.
- The second Expanded Access patient (EA2) demonstrated improved walking as measured by gait stability and endurance
- The patient showed clinically significant improvement in the Expanded Disability Status Scale (EDSS).
- The 6-month PET imaging will occur in Q4 2022 to confirm simultaneous improvements in microglial activation
NEW YORK, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the second patient (“EA2”) with non-active secondary progressive multiple sclerosis (SPMS) receiving intranasal foralumab has shown additional clinical improvements as measured by the Expanded Disability Status Scale (EDSS), a standard clinical assessment.
On September 12th, 2022, this patient had walked 100 meters without a cane or need for rest. Prior to this, on June 8, 2022, the patient required a cane to walk 100 meters. This corresponds with a clinically meaningful improvement in the EDSS score of 0.5. The patient’s pyramidal score remained stable and did not worsen over time. This patient has received a total of 10.5 treatment cycles of foralumab to date.
“Coupled with our PET imaging data demonstrating inhibition of microglial activation, I am truly excited and encouraged by the clinical benefits shown so far for the first two expanded access patients receiving intranasal foralumab for SPMS,” commented Gabriele Cerrone, Executive Chairman and interim Chief Executive Officer of Tiziana. “This program is a top priority for us, and we expect to enroll four additional patients with SPMS at Brigham and Women’s Hospital (BWH) in Q4 2022.”
Howard L. Weiner, M.D., Co-Director of the Ann Romney Center for Neurologic Diseases at BWH and Chairman of Tiziana's Scientific Advisory Board, stated, “I am pleased, but not surprised to see additional clinical improvement in the second patient. SPMS represents an advanced stage of multiple sclerosis with few treatment options and creates a severe burden on patients.”
Dr. Tanuja Chitnis, M.D., Professor of Neurology and the Principal investigator of the clinical study at BWH said, “Patients with non-active SPMS normally do not improve over a six-month time course. I am very encouraged by these results and look forward to seeing this patient’s PET imaging to determine if there is a continued reduction in microglial activation to correlate with the improvement we are observing in the patient’s clinical exam.”
About Foralumab
Foralumab (formerly NI-0401), the only entirely human anti-CD3 mAb, has shown reduced release of cytokines after IV administration in healthy volunteers and in patients with Crohn's disease. In a humanized mouse model (NOD/SCID IL2γc-/-), it was shown that while targeting the T-cell receptor, orally administered foralumab modulates immune responses of the T-cells and enhances regulatory T-cells (Tregs), thereby providing therapeutic benefit in treating inflammatory and autoimmune diseases without the occurrence of potential adverse events usually associated with parenteral mAb therapy. Once a day treatment for 10 consecutive days with intranasal foralumab was both well tolerated and produced clinical responses in COVID-19 patients. Based on these studies, the intranasal and oral administration of Foralumab offers the potential to become a well-tolerated immunotherapy for autoimmune and inflammatory diseases by the induction of Tregs.
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For further inquiries:
Tiziana Life Sciences Ltd
Hana Malik, Business Development and Investor Relations Manager
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
Investors:
Irina Koffler
LifeSci Advisors, LLC
646.970.4681
ikoffler@lifesciadvisors.com
FAQ
What is the latest update from Tiziana Life Sciences regarding TLSA?
How did the second patient in Tiziana's Expanded Access program perform?
What is the expected timeline for Tiziana Life Sciences' PET imaging results?
What does the improvement in EDSS score signify for TLSA's patient?
